PF-05221304

liver-targeted acetyl-CoA carboxylase inhibitor

oral hepatoselective activity obeserved in HV

from opt. of prior candidate for liver uptake

J. Med. Chem., Sep. 18, 2020

Pfizer, Cambridge, MA / Groton, CT

PF-05221304 is a liver targeted inhibitor of acetyl-CoA carboxylase (ACC). ACC is a key regulator of lipid metabolism, and there has been significant interest in ACC inhibitors for the treatment…

become a member to continue reading

Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.

Stay up-to-date and save more time with exclusive members-only content
On-board new team members with educational content and case studies

Generate ideas and discussion with easy-to-read slide decks
Generate ideas and discussion with easy-to-read slide decks